Literature DB >> 19879356

Mouse models of neurological disorders: a view from the blood-brain barrier.

William A Banks1.   

Abstract

The number of disease models that involve an aspect of blood-brain barrier (BBB) dysregulation have increased tremendously. The main factors contributing to this expansion have been an increased number of diseases in which the BBB is known to be involved, an increase in the known functions of the BBB, and an increase in the number of models and tools with which those diverse functions can be studied. In many cases, the BBB may be a target of disease; current thinking would include hypertensive encephalopathy and perhaps stroke in this category. Another category are those diseases in which special attributes of the BBB may predispose to disease; for example, the ability of a pathogen to cross the BBB often depends on the pathogen's ability to invoke transcytotic pathways in the brain endothelial or choroid plexus cell. Of special interest are those diseases in which the BBB may be the primary seat of disease or play a major role in the onset or progression of the disease. An increasing number of diseases are so categorized in which BBB dysfunction or dysregulation plays a major role; this review highlights such roles for the BBB including those proposed for Alzheimer's disease and obesity. Published by Elsevier B.V.

Entities:  

Mesh:

Year:  2009        PMID: 19879356      PMCID: PMC2891624          DOI: 10.1016/j.bbadis.2009.10.011

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  163 in total

1.  Distribution of the blood-brain barrier in heterotopic brain transplants and its relationship to the lesions of EAE.

Authors:  R L Knobler; J C Marini; D Goldowitz; F D Lublin
Journal:  J Neuropathol Exp Neurol       Date:  1992-01       Impact factor: 3.685

2.  Blood-brain barrier abnormalities in Alzheimer's disease.

Authors:  S I Harik; R N Kalaria
Journal:  Ann N Y Acad Sci       Date:  1991       Impact factor: 5.691

3.  Mononuclear cell trafficking and plasma protein extravasation into the CNS during chronic relapsing experimental allergic encephalomyelitis in Biozzi AB/H mice.

Authors:  C Butter; D Baker; J K O'Neill; J L Turk
Journal:  J Neurol Sci       Date:  1991-07       Impact factor: 3.181

Review 4.  Can disturbed brain microcirculation cause Alzheimer's disease?

Authors:  J C de la Torre; T Mussivand
Journal:  Neurol Res       Date:  1993-06       Impact factor: 2.448

5.  In vitro and in vivo transport of zidovudine (AZT) across the blood-brain barrier and the effect of transport inhibitors.

Authors:  R Masereeuw; U Jaehde; M W Langemeijer; A G de Boer; D D Breimer
Journal:  Pharm Res       Date:  1994-02       Impact factor: 4.200

6.  Induction of active and adoptive relapsing experimental autoimmune encephalomyelitis (EAE) using an encephalitogenic epitope of proteolipid protein.

Authors:  B L McRae; M K Kennedy; L J Tan; M C Dal Canto; K S Picha; S D Miller
Journal:  J Neuroimmunol       Date:  1992-06       Impact factor: 3.478

7.  Effect of diet-induced obesity and experimental hyperinsulinemia on insulin uptake into CSF of the rat.

Authors:  P A Israel; C R Park; M W Schwartz; P K Green; A J Sipols; S C Woods; D Porte; D P Figlewicz
Journal:  Brain Res Bull       Date:  1993       Impact factor: 4.077

8.  Alzheimer disease amyloid beta protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum.

Authors:  N Arispe; E Rojas; H B Pollard
Journal:  Proc Natl Acad Sci U S A       Date:  1993-01-15       Impact factor: 11.205

Review 9.  The role of the blood-brain barrier in HIV infection of the central nervous system.

Authors:  A A Hurwitz; J W Berman; W D Lyman
Journal:  Adv Neuroimmunol       Date:  1994

10.  Alzheimer disease amyloid proteins inhibit brain endothelial cell proliferation in vitro.

Authors:  P Grammas; T Botchlet; R Fugate; M J Ball; A E Roher
Journal:  Dementia       Date:  1995 May-Jun
View more
  7 in total

1.  Dendritic degeneration, neurovascular defects, and inflammation precede neuronal loss in a mouse model for tau-mediated neurodegeneration.

Authors:  Tomasz Jaworski; Benoit Lechat; David Demedts; Lies Gielis; Herman Devijver; Peter Borghgraef; Hans Duimel; Fons Verheyen; Sebastian Kügler; Fred Van Leuven
Journal:  Am J Pathol       Date:  2011-08-10       Impact factor: 4.307

2.  Leveraging the Dynamic Blood-Brain Barrier for Central Nervous System Nanoparticle-based Drug Delivery Applications.

Authors:  Connor Copeland; Sarah E Stabenfeldt
Journal:  Curr Opin Biomed Eng       Date:  2020-04-14

3.  Protein kinase C activation modulates reversible increase in cortical blood-brain barrier permeability and tight junction protein expression during hypoxia and posthypoxic reoxygenation.

Authors:  Colin L Willis; Diana S Meske; Thomas P Davis
Journal:  J Cereb Blood Flow Metab       Date:  2010-08-11       Impact factor: 6.200

4.  Astrocyte-derived interleukin-15 exacerbates ischemic brain injury via propagation of cellular immunity.

Authors:  Minshu Li; Zhiguo Li; Yang Yao; Wei-Na Jin; Kristofer Wood; Qiang Liu; Fu-Dong Shi; Junwei Hao
Journal:  Proc Natl Acad Sci U S A       Date:  2016-12-19       Impact factor: 11.205

5.  Evaluation of soluble junctional adhesion molecule-A as a biomarker of human brain endothelial barrier breakdown.

Authors:  Axel Haarmann; Annika Deiss; Jürgen Prochaska; Christian Foerch; Babette Weksler; Ignacio Romero; Pierre-Olivier Couraud; Guido Stoll; Peter Rieckmann; Mathias Buttmann
Journal:  PLoS One       Date:  2010-10-21       Impact factor: 3.240

6.  Loss of vascular early response gene reduces edema formation after experimental stroke.

Authors:  Fudong Liu; L Christine Turtzo; Jun Li; Jean Regard; Paul Worley; Neer Zeevi; Louise D McCullough
Journal:  Exp Transl Stroke Med       Date:  2012-06-08

7.  TNAP and EHD1 are over-expressed in bovine brain capillary endothelial cells after the re-induction of blood-brain barrier properties.

Authors:  Barbara Deracinois; Sophie Duban-Deweer; Gwënaël Pottiez; Roméo Cecchelli; Yannis Karamanos; Christophe Flahaut
Journal:  PLoS One       Date:  2012-10-31       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.